You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Claims for Patent: 11,185,541

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,185,541

Title:	Methods for treating antipsychotic-induced weight gain
Abstract:	The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Inventor(s):	Deaver; Daniel R. (Wilmington, NC), Todtenkopf; Mark (Franklin, MA)
Assignee:	Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:	16/899,708
Patent Claims:	1. A method for treating schizophrenia, comprising orally administering, daily, to a patient need thereof, a pharmaceutical composition comprising: olanzapine; 10 mg of a compound having the structure: ##STR00022## or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. 2. The method according to claim 1, wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 3. The method according to claim 1, wherein the pharmaceutical composition is a tablet. 4. The method according to claim 1, wherein the pharmaceutical composition further comprises lactose. 5. The method according to claim 1, wherein the pharmaceutical composition further comprises magnesium stearate. 6. The method according to claim 5, wherein the pharmaceutical composition further comprises lactose. 7. A method for treating schizophrenia in patient in need thereof comprising: orally administering daily to the patient 10 mg, based on the free base weight, a compound having the structure: ##STR00023## or a pharmaceutically acceptable salt thereof; and administering to the patient, daily, an antipsychotic, wherein the antipsychotic is olanzapine. 8. The method according to claim 7, wherein administering the compound and administering the olanzapine occurs concurrently. 9. The method according to claim 7, wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 10. A method for treating schizophrenia in a patient in need thereof, comprising orally administering, daily, to a patient, a pharmaceutical composition comprising: 10 mg, based on the free base weight, of a compound having the structure: ##STR00024## olanzapine; and a pharmaceutically acceptable excipient; wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 11. The method according to claim 10, wherein the pharmaceutical composition is a tablet.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.